Trial Profile
An open label prospective pilot-study to determine the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients with coronary artery disease and hypertension.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 19 Apr 2012
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary)
- Indications Hypertension
- Focus Pharmacodynamics
- Acronyms AGILITY
- 14 Apr 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 16 Jun 2011 New trial record